Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07033585
Active, not recruiting Phase 2/3

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

NCT07033585 · tracked via the Priya Life Science USA tracker
Sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Phase
Phase 2/3
Started
2026-06-15
Last updated
2026-08-27

Condition(s) studied

Type 2 Diabetes

Investigational drug(s) / intervention(s)

Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes →China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes →

Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes: Farxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers

China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes: China Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers

Study summary

Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers

Eligibility

Sex
ALL
Min age
24 Years
Max age
64 Years
Healthy volunteers
No
* Select 600 type 2 diabetes patients with controlled cancers. * Dosage Duration at least 90 days Inclusion Criteria: * 1\. Clinical diagnosis of type 2 diabetes * 2\. Controlled cancers * 3\. Suitable for enough blood-drawing * 4\. Random and double blind * 5\. Measurable disease * 6\. Adequate organ functions * 7\. Adequate performance status * 8\. Age 24 years old and over * 9\. Sign an informed consent form * 10\. Receive blood-drawing Exclusion Criteria: * 1\. Uncontrolled cancers * 2\. Pregnancy * 3\. Breast-feeding * 4\. The patients with other serious intercurrent illness or infectious diseases * 5\. The participating patients have serious side effects. * 6\. Serious Allergy to Drugs * 7\. Thrombus or Bleed Tendency * 8\. Serious Risks or Serious Adverse Events of the drug product * 9\. The prohibition of drug products * 10\. Have no therapeutic effects

Primary outcome measure(s)

  • Detect Hemoglobin A1c (HbA1c) — Duration up to 90 days
    Draw blood Detect Hemoglobin A1c (HbA1c)
  • Detect fasting blood glucose (FBG) — Duration up to 90 days
    Draw blood Detect fasting blood glucose (FBG)
  • Detect 2-hour postprandial blood glucose (2 hPBG) — Duration up to 90 days
    Draw blood Detect 2-hour postprandial blood glucose (2 hPBG)
  • Detect fasting insulin (FINS) — Duration up to 90 days
    Draw blood Detect fasting insulin (FINS)
  • Detect 2-hour postprandial insulin (2 hPINS) — Duration up to 90 days
    Draw blood Detect 2-hour postprandial insulin (2 hPINS)

Trial sites (1)

FacilityCityRegionStatus
Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701 Rockville Maryland

More Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair trials in the USA

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms Active, not recruiting

Other trials for the same condition

Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry) Enrolling by invitation
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Active, not recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets Active, not recruiting
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07033585 on ClinicalTrials.gov ↗ ← All trials in the USA